Continuous combined hormone replacement therapy and risk of endometrial cancer

American Journal of Obstetrics and Gynecology

Volumn 183, Issue 6, 2000, Pages 1456-1461

  Hill, Deirdre A ^a,b   Weiss, Noel S ^a,b   Beresford, Shirley A A ^a,b   Voigt, Lynda F ^b   Daling, Janet R ^a,b   Stanford, Janet L ^a,b   Self, Steve ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Endometrial neoplasms; Estrogen replacement therapy; Estrogens; Menopause; Progestational hormones

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; CANCER RISK; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

EID: 0034522244     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.108081     Document Type: Article

References (26)

1. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
2. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
3. Estrogen replacement therapy and fractures in older women
4. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
5. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
6. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium
7. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
8. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial
9. Hormone replacement therapy and endometrial cancer risk: A metaanalysis
10. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
11. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
12. Estrogens, progesterone, and endometrial cancer
13. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
14. Estrogen-progestin replacement therapy and endometrial cancer
15. Risk of endometrial cancer following estrogen replacement with and without progestins
16. Sampling methods for random digit dialing
17. Reliability, of recall of drug usage and other health-related information
18. Exogenous estrogens and endometrial cancer: A case-control study and assessment of potential biases
19. Agreement between interview information and physician records on history of menopausal estrogen use
20. Pictorially assisted recall of past hormone use in case-control studies
21. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy
22. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate
23. Recent changes in attack and survival rates of acute myocardial infarction (1975 through 1981). The Worcester Heart Attack Study
24. Hip fracture incidence and mortality in New England
25. Survival among women with endometrial cancer: A comparison of estrogen users and nonusers
26. Women's beliefs and decisions about hormone replacement therapy